Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 28 · below the Ichimoku cloud · RSI 45 · MACD below its signal
None of the 29 investors followed here reported a position in PLRZ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PLRZ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 30, 2026 | Carmel LironDirector | Sale at price 12.36 per share. | 942 | $11.64K |
| Mar 30, 2026 | Izraeli TomerChief Executive Officer | Sale at price 11.85 per share. | 500 | $5.92K |
| Mar 30, 2026 | Adler OzDirector | Sale at price 12.05 per share. | 3.3K | $39.67K |
| Mar 29, 2026 | Carmel LironDirector | Sale at price 11.00 per share. | 100 | $1.10K |
| Mar 29, 2026 | Turgeman TidharChief Technology Officer | Sale at price 10.90 per share. | 2.9K | $31.80K |
| Mar 29, 2026 | Izraeli TomerChief Executive Officer | Sale at price 10.90 per share. | 3.9K | $42.51K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 35.6 | 8.5 | -6.5 | 36.1 | 8.0 | -27.1 | -10.1 | 29.0 | -25.7 | -9.7 | +14.7% | ||
| 2025 | -47.0 | -34.2 | -51.3 | -16.0 | -98.8 | -19.1 | 69.1 | -12.8 | -0.9 | -5.6 | -47.5 | 164.5 | −99.7% |
| 2024 | -32.0 | 131.3 | +57.2% |
No analyst coverage for this instrument.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.